Digital Endpoint Development for Alzheimer’s Disease: The Importance of Patients as Partners

Life Sciences, Clinical Trials, Pharmaceutical,
  • Tuesday, May 23, 2023

Digital health technologies (DHTs) like smartphones and wearable sensors hold great promise to advance drug development and discovery in neurodegenerative diseases, particularly Alzheimer’s disease. Through objective, continuous, remote capture of real-world outcomes, DHTs have the capacity to measure the impact of novel treatments on how patients with Alzheimer’s disease feel and function in their real-world environments, which, in turn, enables the development of drugs that improve aspects of health that matter most to patients. A digital endpoint derived from DHTs thus gives deeper insight on a patient’s health.

To ensure the development of patient-centric endpoints in Alzheimer’s disease drug development, engaging patients as partners throughout the process of digital endpoint development is critical. In this webinar, the featured speakers bring together stakeholders representing the perspectives of pharma, technology developers, and most importantly, patients. The panel will discuss different approaches to patient engagement in digital health.

This webinar will close with a discussion between stakeholders focused on opportunities for promoting patient centricity in Alzheimer’s disease drug development and identify areas for improvement.

Register for this webinar today to understand how patient engagement can enhance digital endpoint development in Alzheimer’s disease clinical trials.


(Moderator) Jen Blankenship, VivoSense

(Moderator) Jen Blankenship, Senior Research Scientist, VivoSense

Jen is a Senior Research Scientist at VivoSense. Jen obtained a PhD in Kinesiology at the University of Massachusetts, Amherst. She has extensive experience deploying wearable sensors and other digital health technologies in real-world study designs to understand the impact of novel treatments and therapeutics on aspects of daily life. At VivoSense, Jen is working to develop novel digital clinical measures derived from wearable sensors that capture aspects of life that matter to patients with Alzheimer’s disease.

Message Presenter
Shelby Bachman, VivoSense

Shelby Bachman, Research Scientist, VivoSense

Shelby Bachman is a Research Scientist at VivoSense with expertise in neuroscience, gerontology and statistics. She obtained a PhD in gerontology during which she studied neural and physiological factors that contribute to successful aging. At VivoSense, Shelby uses data from wearable sensors to develop measures of real-world behavior that capture how patients feel and function.

Message Presenter
Jelena Curcic, (NIBR)/Biomarker Development

Jelena Curcic, Associate Director & Senior Principal Data Scientist, Novartis Institutes for Biomedical Research (NIBR)/Biomarker Development

Dr. Jelena Curcic is a biomedical engineer working as a Senior Data Scientist at Novartis Institutes for Biomedical Research (NIBR) in Basel, Switzerland with the expertise in development, deployment and advanced analytics of digital biomarkers in neuroscience. Her special topics of interest are using technology to measure cognition and neuropsychiatric symptoms in Alzheimer’s disease and mood disorders.

Message Presenter
Francesca Cormac, Cambridge Cognition

Francesca Cormac, Chief Scientist, Cambridge Cognition

Francesca Cormac is the Chief Scientist at Cambridge Cognition. She has extensive experience in statistics, cognitive neuroscience and cognitive test development in a range of clinical populations. Since joining Cambridge Cognition in 2014, Francesca has worked to develop novel cognitive testing methodology to support high-frequency, near patient testing using digital technology, providing researchers and healthcare providers with unique insights into cognitive health. Francesca obtained a PhD in dementia with Lewy bodies at Newcastle University, followed by post-doctoral and academic positions at University College London and at the Medical Research Council in Cambridge. She maintains academic collaborations focused on neurological disorders, ageing and dementia.

Message Presenter
Michael Ellenbogen, International Dementia Advocate & Connecter

Michael Ellenbogen, International Dementia Advocate & Connecter

Michael Ellenbogen was diagnosed with Young-Onset Alzheimer’s disease at the age of 49. Prior to his diagnosis, he was a network operations manager for a Fortune 500 financial institution. Difficulty with work-related tasks eventually led to his early retirement. As a world-renowned International Dementia Advocate & Connecter, he has been featured in nationally syndicated TV, radio and other media outlets. He has written for blogs, newspapers, journals and websites and shared his personal perspective as a guest speaker. Michael served on the PA Alzheimer’s Disease Planning Committee and other advisory councils. He testified before the government, and has three letters published in the US Congressional Record. He was a regular speaker at NAPA and was featured in the ADI’s 2012 World Alzheimer’s Report. He represented the US/world for people living with dementia at the World Health Organization in Geneva. He is interested in motivating those with Alzheimer’s to raise their voices and reduce the stigma surrounding the disease. Michael wrote about his journey with the disease in his book entitled “From the Corner Office to Alzheimer’s.”

Message Presenter

Who Should Attend?

  • Drug developers (clinical scientists, data scientists)
  • Health technology providers (engineers, developers, UX designers)
  • Patients (patient advocates, care partners)
  • Healthcare practitioners
  • CROs
  • Pharmaceutical companies involved in digital innovation in clinical trials

What You Will Learn

Attendees will discover:

  • Challenges and shortcomings of clinical trials from the patient perspective
  • Approaches to better understand study participant burden through patient engagement groups
  • Frameworks to incorporate the patient perspective in outcome measure development

Xtalks Partner


VivoSense, Inc., develops and validates real-world digital clinical measures and provides end-to-end services and solutions for their delivery in clinical trials. Our hypothesis driven framework provides analytical and clinical validation leading to FDA approval. VivoSense delivers novel digital biomarkers from wearable sensor data which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials. VivoSense is dedicated to improving patient clinical research and care.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account